Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Recently, the U.S. Food and Drug Administration (FDA) issued a Drug Safety Communication that warns of an increased risk of diabetic ketoacidosis (DKA) with uncharacteristically mild to moderate glucose elevations (euglycemic DKA [euDKA]) associated with the use of all the approved sodium-glucose cotransporter 2 (SGLT2) inhibitors (1).This Communication was based on 20 clinical cases requiring hospitalization captured between March 2013 and June 2014 in the FDA Adverse Event Reporting System database.The scarce clinical data provided suggested that most of the DKA cases were reported in patients with type 2 diabetes (T2D), for whom this class of agents is indicated; most likely, however, they were insulintreated patients, some with type 1 diabetes (T1D).The FDA also identified potential triggering factors such as intercurrent illness, reduced food and fluid intake, reduced insulin doses, and history of alcohol intake.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients with either T1DM or T2DM taking insulin are at particular risk, with the greatest risk for ketoacidosis in T1DM.”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [90]
In the citing paper
“Euglycemic ketoacidosis with minimal to no elevation in blood glucose levels may occur in patients taking SGLT2 inhibitors due to increased fatty acid oxidation and glucagon release along with decreased insulin secretion (89,90).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [90]
Citations
Cites
Nathan, D. M., & for the DCCT/EDIC Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2112 · Cited by 1,832
Miller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., & Woerle, H.-J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72227 · Cited by 1,134 · cited 4×
“Thus, in SGLT2-treated T2D patients (17), the lower insulin-to-glucagon ratio stimulated lipolysis (circulating FFAs were ;40% higher during the meal) and enhanced lipid oxidation (by 20% on av-”
BackgroundInfluentialSelf-citationPeters, A. L., Buschur, E. O., Buse, J. B., Cohan, P., Diner, J. C., & Hirsch, I. B. (2015) · Diabetes Care · doi:10.2337/dc15-0843 · Cited by 849
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T. V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul-Ghani, M. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70704 · Cited by 795 · cited 1×
“of the euglycemic insulin clamp, as a result of attenuated glucotoxicity (21).”
BackgroundInternational Textbook of Diabetes Mellitus
(2004) · Wiley eBooks · doi:10.1002/0470862092 · Cited by 725
Bonner, C., Kerr-Conte, J., Gmyr, V., Queniat, G., Moerman, E., Thévenet, J., Beaucamps, C., Delalleau, N., Popescu, I., Malaisse, W. J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3828 · Cited by 670
Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program
Erondu, N., Desai, M., Ways, K., & Meininger, G. (2015) · Diabetes Care · doi:10.2337/dc15-1251 · Cited by 324
Euglycaemic Diabetic Ketoacidosis
Munro, J. F., Campbell, I. W., McCuish, A. C., & Duncan, L. J. P. (1973) · BMJ · doi:10.1136/bmj.2.5866.578 · Cited by 323
Insulin within islets is a physiologic glucagon release inhibitor
Maruyama, H., Hisatomi, A., Orci, L., Grodsky, G. M., & Unger, R. H. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111658 · Cited by 303 · cited 1×
“In contrast, plasma glucagon concentrations increased significantly, partly because of a diminished paracrine inhibition by insulin (18) and possibly also because of decreased SGLT2-mediated glucose transport intoa-cells (19).”
Background
Cited by
CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
Ferrannini, E., Mark, M., & Mayoux, E. (2016) · Diabetes Care · doi:10.2337/dc16-0330 · Cited by 975
Self-citationFerrannini, E., Baldi, S., Frascerra, S., Astiarraga, B., Heise, T., Bizzotto, R., Mari, A., Pieber, T. R., & Muscelli, E. (2016) · Diabetes · doi:10.2337/db15-1356 · Cited by 712
Self-citationAn update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus
Hsia, D. S., Grove, O., & Cefalu, W. T. (2017) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000311 · Cited by 508
Wu, J. H. Y., Foote, C., Blomster, J., Toyama, T., Perkovic, V., Sundström, J., & Neal, B. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00052-8 · Cited by 474
Lytvyn, Y., Bjornstad, P., Udell, J. A., Lovshin, J. A., & Cherney, D. Z. I. (2017) · Circulation · doi:10.1161/circulationaha.117.030012 · Cited by 459
Das, S. R., Everett, B. M., Birtcher, K. K., Brown, J. M., Januzzi, J. L., Kalyani, R. R., Kosiborod, M., Magwire, M., Morris, P. B., Neumiller, J. J., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.05.037 · Cited by 466
Dhatariya, K. K., Glaser, N. S., Codner, E., & Umpierrez, G. E. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0165-1 · Cited by 461
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
Tahrani, A. A., Barnett, A. H., & Bailey, C. J. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.86 · Cited by 398
Ketone bodies: from enemy to friend and guardian angel
Kolb, H., Kempf, K., Röhling, M., Lenzen-Schulte, M., Schloot, N. C., & Martin, S. (2021) · BMC Medicine · doi:10.1186/s12916-021-02185-0 · Cited by 361
Danne, T., Garg, S., Peters, A. L., Buse, J. B., Mathieu, C., Pettus, J. H., Alexander, C. M., Battelino, T., Ampudia-Blasco, F. J., Bode, B. W., et al. (2019) · Diabetes Care · doi:10.2337/dc18-2316 · Cited by 379
Self-citationHandelsman, Y., Henry, R. R., Bloomgarden, Z. T., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Ferrannini, E., Fonseca, V. A., Garber, A. J., Grunberger, G., et al. (2016) · Endocrine Practice · doi:10.4158/ep161292.ps · Cited by 358
Self-citationSodium-Glucose Co-transporters and Their Inhibition: Clinical Physiology
Ferrannini, E. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.04.011 · Cited by 340
Self-citationGoldenberg, R. M., Berard, L. D., Cheng, A. Y. Y., Gilbert, J. D., Verma, S., Woo, V. C., & Yale, J.-F. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.11.002 · Cited by 354
Mathieu, C., Zinman, B., Hemmingsson, J. U., Woo, V., Colman, P., Christiansen, E., Linder, M., Bode, B., & for the ADJUNCT ONE Investigators (2016) · Diabetes Care · doi:10.2337/dc16-0691 · Cited by 347
Puckrin, R., Saltiel, M.-P., Reynier, P., Azoulay, L., Yu, O. H. Y., & Filion, K. B. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1116-0 · Cited by 278
Das, S. R., Everett, B. M., Birtcher, K. K., Brown, J. M., Cefalu, W. T., Januzzi, J. L., Kalyani, R. R., Kosiborod, M., Magwire, M. L., Morris, P. B., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.09.020 · Cited by 300
Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors
Scheen, A. J. (2018) · Circulation Research · doi:10.1161/circresaha.117.311588 · Cited by 286
Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus
Scheen, A. J. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0392-2 · Cited by 267
Ketoacidosis associated with SGLT2 inhibitor treatment: analysis of FAERS data
Blau, J. E., Tella, S. H., Taylor, S. I., & Rother, K. I. (2017) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2924 · Cited by 271
Pharmacologic Glycemic Management of Type 2 Diabetes in Adults
Lipscombe, L., Booth, G., Butalia, S., Dasgupta, K., Eurich, D. T., Goldenberg, R., Khan, N., MacCallum, L., Shah, B. R., & Simpson, S. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.034 · Cited by 246
Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials
Levine, M. J. (2017) · Current Diabetes Reviews · doi:10.2174/1573399812666160613113556 · Cited by 230
SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms
Osataphan, S., Macchi, C., Singhal, G., Chimene-Weiss, J., Sales, V., Kozuka, C., Dreyfuss, J. M., Pan, H., Tangcharoenpaisan, Y., Morningstar, J., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.123130 · Cited by 228
Qiu, H., Novikov, A., & Vallon, V. (2017) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2886 · Cited by 226
SGLT2 Inhibition in the Diabetic Kidney—From Mechanisms to Clinical Outcome
van Bommel, E. J. M., Muskiet, M. H. A., Tonneijck, L., Kramer, M. H. H., Nieuwdorp, M., & van Raalte, D. H. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06080616 · Cited by 222
Karslioglu French, E., Donihi, A. C., & Korytkowski, M. T. (2019) · BMJ · doi:10.1136/bmj.l1114 · Cited by 200
Breath acetone as a potential marker in clinical practice
Ruzsányi, V., & Péter Kalapos, M. (2017) · Journal of Breath Research · doi:10.1088/1752-7163/aa66d3 · Cited by 195
van Baar, M. J. B., van Ruiten, C. C., Muskiet, M. H. A., van Bloemendaal, L., IJzerman, R. G., & van Raalte, D. H. (2018) · Diabetes Care · doi:10.2337/dc18-0588 · Cited by 199
Diabetic Gastroparesis: Principles and Current Trends in Management
Krishnasamy, S., & Abell, T. L. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0454-9 · Cited by 199
“Dehydration and euglycemic ketoacidosis are a potential risk, but the direct impact of SGLT-2i on DGp is not clear at this time [98].”
BackgroundCognitive impairment and type 2 diabetes mellitus: Focus of SGLT2 inhibitors treatment
Rizzo, M. R., Di Meo, I., Polito, R., Auriemma, M. C., Gambardella, A., di Mauro, G., Capuano, A., & Paolisso, G. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106062 · Cited by 178
Ferrannini, E., Baldi, S., Frascerra, S., Astiarraga, B., Barsotti, E., Clerico, A., & Muscelli, E. (2017) · Diabetes Care · doi:10.2337/dc16-2724 · Cited by 181
Self-citationEuglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors
Chow, E., Clement, S., & Garg, R. (2023) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2023-003666 · Cited by 164
Uric acid and the cardio‐renal effects of SGLT2 inhibitors
Bailey, C. J. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13670 · Cited by 183
Burke, K. R., Schumacher, C. A., & Harpe, S. E. (2017) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1881 · Cited by 184
Liu, J., Li, L., Li, S., Wang, Y., Qin, X., Deng, K., Liu, Y., Zou, K., & Sun, X. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14075 · Cited by 176
An update on the safety of SGLT2 inhibitors
Scheen, A. J. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1602116 · Cited by 174
Euglycemic diabetic ketoacidosis
Barski, L., Eshkoli, T., Brandstaetter, E., & Jotkowitz, A. (2019) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2019.03.014 · Cited by 176
Sodium—Glucose cotransporter inhibitors and oxidative stress: An update
Yaribeygi, H., Atkin, S. L., Butler, A. E., & Sahebkar, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.26760 · Cited by 167
Schernthaner, G., Shehadeh, N., Ametov, A. S., Bazarova, A. V., Ebrahimi, F., Fasching, P., Janež, A., Kempler, P., Konrāde, I., Lalić, N. M., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01154-w · Cited by 164
The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes
Hædersdal, S., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.12.003 · Cited by 162
“The SGLT2i-induced increase in glucagon may provide a partial explanation for this observation given that increased levels of glucagon are linked with diabetic ketoacidosis.(192)”
Documento de información y consenso para la detección y manejo de la enfermedad renal crónica
Maset, R. G., Bover, J., Segura, J., Diezhandino, M. G., del Hoyo, J. C., Martín, J. E. S., Fácila, L., Gamarra, J., García‐Donaire, J. A., Matarin, L. G., et al. (2021) · Nefrología · doi:10.1016/j.nefro.2021.07.010 · Cited by 206
Empagliflozin: A Review in Type 2 Diabetes
Frampton, J. E. (2018) · Drugs · doi:10.1007/s40265-018-0937-z · Cited by 171
Euglycemic diabetic ketoacidosis: etiologies, evaluation, and management
Long, B., Lentz, S., Koyfman, A., & Gottlieb, M. (2021) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2021.02.015 · Cited by 150
Gourdy, P., Darmon, P., Diévart, F., Halimi, J., & Guerci, B. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01798-4 · Cited by 157
Kelly, T., Unwin, D., & Finucane, F. M. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17072557 · Cited by 156
Euglycemic diabetic ketoacidosis: a diagnostic and therapeutic dilemma
Rawla, P., Vellipuram, A. R., Bandaru, S. S., & Pradeep Raj, J. (2017) · Endocrinology, Diabetes & Metabolism Case Reports · doi:10.1530/edm-17-0081 · Cited by 139
Tuttle, K. R., Brosius, F. C., Cavender, M. A., Fioretto, P., Fowler, K. J., Heerspink, H. J. L., Manley, T., McGuire, D. K., Molitch, M. E., Mottl, A. K., et al. (2020) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2020.08.003 · Cited by 142
Euglycemic Ketoacidosis as a Complication of SGLT2 Inhibitor Therapy
Palmer, B. F., & Clegg, D. J. (2021) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.17621120 · Cited by 162
Schwaiger, E., Burghart, L., Signorini, L., Ristl, R., Kopecky, C., Tura, A., Pacini, G., Wrba, T., Antlanger, M., Schmaldienst, S., et al. (2019) · American Journal of Transplantation · doi:10.1111/ajt.15223 · Cited by 133
Kidney-Protective Effects of SGLT2 Inhibitors
Palmer, B. F., & Clegg, D. J. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09380822 · Cited by 137
Safety of Sodium-Glucose Co-Transporter 2 Inhibitors
McGill, J. B., & Subramanian, S. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.10.029 · Cited by 127
Hamblin, P. S., Wong, R., Ekinci, E. I., Fourlanos, S., Shah, S., Jones, A. R., Hare, M. J. L., Calder, G. L., Epa, D. S., George, E. M., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00139 · Cited by 126
Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies
Thrasher, J. R. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.04.004 · Cited by 146
SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: Balancing benefits and risks
Taylor, S. I., Blau, J. E., Rother, K. I., & Beitelshees, A. L. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30154-8 · Cited by 124
Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists
Wilcox, T., Block, C. E. M. D., Schwartzbard, A. Z., & Newman, J. D. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.02.056 · Cited by 134
Tuttle, K. R., Brosius, F. C., Cavender, M. A., Fioretto, P., Fowler, K. J., Heerspink, H. J. L., Manley, T., McGuire, D. K., Molitch, M. E., Mottl, A. K., et al. (2021) · Diabetes · doi:10.2337/dbi20-0040 · Cited by 123
“Euglycemic ketoacidosis with minimal to no elevation in blood glucose levels may occur in patients taking SGLT2 inhibitors due to increased fatty acid oxidation and glucagon release along with decreased insulin secretion (89,90).”
BackgroundPharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies
Thrasher, J. R. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.05.009 · Cited by 142
Clinical Considerations for Use of Initial Combination Therapy in Type 2 Diabetes
Cahn, A., & Cefalu, W. T. (2016) · Diabetes Care · doi:10.2337/dcs15-3007 · Cited by 132
Hyperglycemic Emergencies in Adults
Goguen, J., & Gilbert, J. D. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.013 · Cited by 123
Scientific evidence underlying contraindications to the ketogenic diet: An update
Watanabe, M., Tuccinardi, D., Ernesti, I., Basciani, S., Mariani, S., Genco, A., Manfrini, S., Lubrano, C., & Gnessi, L. (2020) · Obesity Reviews · doi:10.1111/obr.13053 · Cited by 124
Bonora, B. M., Avogaro, A., & Fadini, G. P. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13012 · Cited by 118
Cardioprotective Potential of an SGLT2 Inhibitor Against Doxorubicin-Induced Heart Failure
Oh, C., Cho, S., Jang, J., Kim, H., Chun, S., Choi, M., Park, S., & Ko, Y. (2019) · Korean Circulation Journal · doi:10.4070/kcj.2019.0180 · Cited by 116
Insulin-associated weight gain in obese type 2 diabetes mellitus patients: What can be done?
Brown, A., Guess, N., Dornhorst, A., Taheri, S., & Frost, G. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13009 · Cited by 113
SGLT2 Inhibitors: Benefit/Risk Balance
Scheen, A. J. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0789-4 · Cited by 119
Perry, R. J., Rabin-Court, A., Song, J. D., CARDONE, R. L., Wang, Y., Kibbey, R. G., & Shulman, G. I. (2019) · Nature Communications · doi:10.1038/s41467-019-08466-w · Cited by 118
Meyer, E., Gabb, G., & Jesudason, D. (2018) · Diabetes Care · doi:10.2337/dc17-1721 · Cited by 96
Peters, A. L., Henry, R. R., Thakkar, P., Tong, C., & Alba, M. (2016) · Diabetes Care · doi:10.2337/dc15-1995 · Cited by 106
Monami, M., Nreu, B., Zannoni, S., Lualdi, C., & Mannucci, E. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.04.017 · Cited by 111
Newer Perspectives of Mechanisms for Euglycemic Diabetic Ketoacidosis
Yu, X., Zhang, S., & Zhang, L. (2018) · International Journal of Endocrinology · doi:10.1155/2018/7074868 · Cited by 115
Management of Diabetic Ketoacidosis in Children and Adolescents with Type 1 Diabetes Mellitus
Castellanos, L. E., Tuffaha, M., Koren, D., & Levitsky, L. L. (2020) · Pediatric Drugs · doi:10.1007/s40272-020-00397-0 · Cited by 137
Defining and characterising diabetic ketoacidosis in adults
Dhatariya, K. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107797 · Cited by 111
Rådholm, K., Wu, J. H. Y., Wong, M. G., Foote, C., Fulcher, G. R., Mahaffey, K. W., Perkovic, V., & Neal, B. C. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.03.027 · Cited by 101
Musso, G., Gambino, R., Cassader, M., & Paschetta, E. (2019) · BMJ · doi:10.1136/bmj.l1328 · Cited by 102
Sodium‐glucose co‐transporter type‐2 inhibitors: pharmacology and peri‐operative considerations
Milder, D. A., Milder, T. Y., & Kam, P. C. A. (2018) · Anaesthesia · doi:10.1111/anae.14251 · Cited by 97
Chen, J., Fan, F., Wang, J. Y., Long, Y., Gao, C., Stanton, R. C., & Xu, Y. (2017) · Scientific Reports · doi:10.1038/srep44128 · Cited by 92
Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice
Lim, L.-L., Chow, E., & Chan, J. C. N. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00776-2 · Cited by 91
Epidemiology of diabetes mellitus
Mekala, K. C., & Bertoni, A. G. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814833-4.00004-6 · Cited by 88
SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort
Ata, F., Yousaf, Z., Khan, A. A., Razok, A., Akram, J., Ali, E. A. H., Abdalhadi, A., Ibrahim, D. A., Al Mohanadi, D. H. S. H., & Danjuma, M. I. (2021) · Scientific Reports · doi:10.1038/s41598-021-89752-w · Cited by 87
Novel Diabetes Drugs and the Cardiovascular Specialist
Sattar, N. A., Petrie, M. C., Zinman, B., & Januzzi, J. L. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.04.014 · Cited by 92
Ivers, N. M., Jiang, M., Alloo, J., Singer, A. G., Ngui, D., Casey, C. G., & Yu, C. H. Y. (2019) · Europe PMC (PubMed Central) · Cited by 84
Johnston, R., Uthman, O. A., Cummins, E., Clar, C., Royle, P., Colquitt, J. L., Tan, B. K., Clegg, A. J., Shantikumar, S., Court, R. A., et al. (2017) · Health Technology Assessment · doi:10.3310/hta21020 · Cited by 90
Wang, Y., Desai, M. G., Ryan, P. B., DeFalco, F., Schuemie, M. J., Stang, P., Berlin, J. A., & Yuan, Ž. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.04.004 · Cited by 91
High prevalence of COVID-19-associated diabetic ketoacidosis in UK secondary care
Goldman, N. R., Fink, D., Cai, J., Lee, Y.-N., & Davies, Z. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108291 · Cited by 84
Diagnóstico e Tratamento da Cetoacidose Diabética Euglicêmica
Santomauro, A. T. M. G., Junior, A. C. S., Raduan, R. A., & Bertoluci, M. C. (2022) · Conectando Pessoas eBooks · doi:10.29327/557753.2022-22 · Cited by 82
Kashiwagi, A., & Maegawa, H. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12644 · Cited by 82
Tang, H., Li, D., Wang, T., Zhai, S., & Song, Y. (2016) · Diabetes Care · doi:10.2337/dc16-0885 · Cited by 80
Donnan, K., & Segar, L. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.01.002 · Cited by 89
Pharmacological aspects of the safety of gliflozins
Faillie, J. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.07.001 · Cited by 81
Bonora, B., Avogaro, A., & Fadini, G. P. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01307-x · Cited by 60
SGLT2 inhibitors: are they safe?
Filippas-Ntekouan, S., Filippatos, T. D., & Elisaf, M. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2018.1394152 · Cited by 80
Myocardial Ketones Metabolism in Heart Failure
Karwi, Q. G., Biswas, D., Pulinilkunnil, T., & Lopaschuk, G. D. (2020) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2020.04.005 · Cited by 75
Dutta, S., Kumar, T., Singh, S., Ambwani, S. R., Charan, J., & Varthya, S. B. (2022) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_644_21 · Cited by 76
Tamargo, J. L. (2019) · European Cardiology Review · doi:10.15420/ecr.2018.34.2 · Cited by 74
Ketoacidosis and SGLT2 Inhibitors: A Narrative Review
Morace, C., Lorello, G., Bellone, F., Quartarone, C., Ruggeri, D., Giandalia, A., Mandraffino, G., Minutoli, L., Squadrito, G., Russo, G. T., et al. (2024) · Metabolites · doi:10.3390/metabo14050264 · Cited by 75
Nagahisa, T., & Saisho, Y. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00680-5 · Cited by 93
Yabe, D., Iwasaki, M., Kuwata, H., Haraguchi, T., Hamamoto, Y., Kurose, T., Sumita, K., Yamazato, H., Kanada, S., & Seino, Y. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12848 · Cited by 69
Impact of sodium–glucose cotransporter 2 inhibitors on blood pressure
Reed, J. W. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s111991 · Cited by 78
Chae, H., Augustin, R., Gatineau, E., Mayoux, E., Bensellam, M., Antoine, N., Khattab, F., Lai, B. K., Brusa, D., Stierstorfer, B., et al. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101071 · Cited by 69
Cai, X., Ji, L., Chen, Y., Yang, W., Zhou, L., Han, X., Zhang, S., & Ji, L. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12625 · Cited by 72
Acute Metabolic Emergencies in Diabetes: DKA, HHS and EDKA
Muneer, M. A., & Akbar, I. (2020) · Advances in experimental medicine and biology · doi:10.1007/5584_2020_545 · Cited by 79
Nanowire Array Breath Acetone Sensor for Diabetes Monitoring
Wei, S., Li, Z., Murugappan, K., Li, Z., Lysevych, M., Vora, K. D., Tan, H. H., Jagadish, C., Karawdeniya, B. I., Nolan, C. J., et al. (2024) · Advanced Science · doi:10.1002/advs.202309481 · Cited by 78
Metadata
- Authors
- Rosenstock, J., & Ferrannini, E.
- Affiliations
- Medical City Dallas Hospital (US)
- Istituto di Fisiologia Clinica (IT)
- Corresponding author
- Rosenstock, Julio
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2015-08-10
- Volume
- 38
- Issue
- 9
- Pages
- 1638-1642
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W1955935325
- Cited by
- 664
- References
- 21
- Citations by year
- 2026: 23 · 2025: 33 · 2024: 55 · 2023: 36 · 2022: 43 · 2021: 68 · 2020: 89 · 2019: 79 · 2018: 67 · 2017: 75 · 2016: 77 · 2015: 18
- FWCI
- 68.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- euglycemic diabetic ketoacidosis, SGLT2 inhibitors, drug safety, type 2 diabetes, type 1 diabetes, insulin-treated patients, adverse drug reactions, risk factors, alcohol consumption, intercurrent illness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.